)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Relay Therapeutics (RLAY) investor relations material
Relay Therapeutics Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Morgan Stanley 23rd Annual Global Healthcare Conference summary10 Sep, 2025
Strategic initiatives and clinical programs
Cash runway extends into 2029, supporting execution of key initiatives.
Lead asset RLY-2608, a PI3K mutant-selective inhibitor, is in phase 3 for post-CDK4/6 metastatic breast cancer.
Triplet combinations with RLY-2608, fulvestrant, and CDK4/6 inhibitors are being explored for CDK4/6 naive patients.
RLY-2608 is also being tested in vascular malformations driven by PI3K alpha mutations.
Two preclinical programs, including an NRAS-specific inhibitor, are advancing toward IND.
Industry landscape and platform innovation
Focus remains on first-in-class, hard-to-drug targets, avoiding "me too" approaches due to global competition, especially from China.
AI is used as an enabling tool to increase efficiency and design better experiments, but human insight remains critical.
The Dynamo® platform integrates computational and experimental approaches, using molecular dynamics, virtual screening, and generative AI to identify and optimize drug candidates.
Anton II supercomputer was instrumental early on, but now cloud and GPU computing provide similar capabilities.
RLY-2608 clinical data and differentiation
RLY-2608 shows a 39% confirmed objective response rate and 10.3 months median PFS in combination with fulvestrant, nearly double that of comparators.
Safety profile is favorable, with low rates of high-grade hyperglycemia and other adverse events compared to existing agents.
Phase 3 Rediscover 2 trial is enrolling, with PFS as the primary endpoint and a hierarchical analysis by mutation class.
Market opportunity in post-CDK4/6 metastatic breast cancer is multi-billion dollar, with 13,000 U.S. and 30,000 global patients; frontline setting could double this.
Peak sales estimates for second-line metastatic setting are around $1 billion, with probability of success between 40% and 65%.
Why 2608's safety profile is key for vascular malformations?
How platform enables Relay's first-in-class strategy?
Key uncertainty for 2608 in vascular malformations?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Relay Therapeutics earnings date
Q3 20257 Nov, 2025
Next Relay Therapeutics earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Relay Therapeutics Inc. is a clinical-stage precision medicine company focusing on the development of small molecule therapeutics. The company operates at the intersection of computational and experimental technologies to enhance drug discovery, particularly in the areas of targeted oncology and genetic diseases. Relay Therapeutics utilizes its proprietary Dynamo platform to address previously intractable or inadequately drugged protein targets by leveraging insights into protein motion and function. This platform integrates various cutting-edge computational and experimental methods to facilitate the drug discovery process. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage